Table 1.
Patient baseline characteristics in all patients with ALK-rearranged NSCLC (N=246)
| Characteristics | ALKi-naïve (n=83) |
ALKi-pretreated* (n=163) |
|---|---|---|
| Age, median (range), years | 55 (22–80) | 52 (24–80) |
| Sex, n (%) | ||
| Female | 44 (53·0) | 88 (54·0) |
| WHO/ECOG performance status, n (%) | ||
| 0 | 25 (30·1) | 38 (23·3) |
| 1 | 51 (61·4) | 104 (63·8) |
| 2 | 7 (8·4) | 20 (12·3) |
| ≥3 | 0 | 1 (0·6) |
| Smoking history | ||
| Never/ex-smoker | 82 (98·8%) | 158 (97·0%) |
| Current smoker | 1 (1·2%) | 5 (3·1%) |
| Race, n (%) | ||
| Caucasian | 48 (57·8) | 108 (66·3) |
| Black | 0 | 4 (2·5) |
| Asian | 35 (42·2) | 47 (28·8) |
| Other | 0 | 4 (2·5) |
| Tumour histology/cytology, n (%) | ||
| Adenocarcinoma | 76 (91·6) | 152 (93·3) |
| Other | 7 (8·4) | 11 (6·7) |
| Site of metastasis, n (%) | ||
| Brain | 26 (31·3) | 98 (60·1) |
| Lung | 62 (74·7) | 111 (68·1) |
| Liver | 30 (36·1) | 68 (41·7) |
| Bone | 26 (31·3) | 69 (42·3) |
| Prior treatment regimens, n (%) | ||
| 0 | 16 (19·3) | 0 |
| 1 | 38 (45·8) | 26 (16·0) |
| 2 | 16 (19·3) | 45 (27·6) |
| 3 | 7 (8·4) | 35 (21·5) |
| ≥4 | 6 (7·2) | 57 (35·0) |
| Median time from initial diagnosis to initiation of ceritinib, months (range) | 8·1 (1·0–109·3) | 21·2 (2·4–174·2) |
ALK=anaplastic lymphoma kinase. NSCLC=non-small-cell lung cancer.
*
All received crizotinib; five patients received the investigational ALK inhibitor CH5424802 after crizotinib.